BASELINE PREDICTORS OF MAJOR ADVERSE EVENTS FOR TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY PATIENTS TREATED AND UNTREATED WITH DISEASE-MODIFYING THERAPY | Publicación